Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabel Heidegger

Showing results (11-20 of 155) with videos related to

Pageof 16
Sort By:
Urologic Oncology|January 19, 2020
Treatment of non-metastatic castration resistant prostate cancer in 2020: What is the best?Isabel Heidegger, Maximilian P Brandt, Matthias M Heck
Cancer Biology & Therapy|February 12, 2011
Targeting the insulin-like growth factor network in cancer therapyIsabel Heidegger, Andreas Pircher, Helmut Klocker, et al.
Cancer Letters|August 2, 2015
The insulin-like growth factor (IGF) axis as an anticancer target in prostate cancerIsabel Heidegger, Petra Massoner, Natalie Sampson, et al.
Der Urologe. Ausg. A|January 11, 2022
[Poly(ADP-ribose) polymerase (PARP-)inhibitors as genetically based precision therapy in metastatic castration-resistent prostate cancer (mCRPC)]Isabel Heidegger, Christoph Becker, Igor Tsaur, et al.
Memo|December 19, 2017
Antiangiogenic therapies in urogenital malignancies: Fiction or fact?Friederike Haidl, David Pfister, Axel Heidenreich, et al.
Urologic Oncology|December 14, 2016
High incidence of clinically significant concomitant prostate cancer in patients undergoing radical cystectomy for bladder cancer: A 10-year single-center experienceIsabel Heidegger, Willi Oberaigner, Wolfgang Horninger, et al.
Aktuelle Urologie|September 6, 2018
[Symptomatic urinary obstruction in patients with metastatic malignancies]Isabel Heidegger, Fabian Steinkohl, Wolfgang Horninger, et al.
Journal of Cancer Research and Clinical Oncology|October 16, 2024
Unraveling molecular characteristics and tumor microenvironment dynamics of neuroendocrine prostate cancerDavid Heimdörfer, Nastasiia Artamonova, Zoran Culig, et al.
Urologic Oncology|June 28, 2020
Emerging promising biomarkers for treatment decision in metastatic castration-resistant prostate cancerMona Kafka, Iris E Eder, Helmut Klocker, et al.
Aktuelle Urologie|January 22, 2026
[Therapy-Associated Neuroendocrine Prostate Cancer (tNEPC): A Diagnostic and Therapeutic Challenge in Uro-Oncology with Emerging Clinical Implications]Gunhild von Amsberg, Arndt Hartmann, Markus Eckstein, et al.
Pageof 16

Showing results (11-20 of 155) with videos related to

Sort By:
Pageof 16
Urologic Oncology|January 19, 2020
Treatment of non-metastatic castration resistant prostate cancer in 2020: What is the best?Isabel Heidegger, Maximilian P Brandt, Matthias M Heck
Cancer Biology & Therapy|February 12, 2011
Targeting the insulin-like growth factor network in cancer therapyIsabel Heidegger, Andreas Pircher, Helmut Klocker, et al.
Cancer Letters|August 2, 2015
The insulin-like growth factor (IGF) axis as an anticancer target in prostate cancerIsabel Heidegger, Petra Massoner, Natalie Sampson, et al.
Der Urologe. Ausg. A|January 11, 2022
[Poly(ADP-ribose) polymerase (PARP-)inhibitors as genetically based precision therapy in metastatic castration-resistent prostate cancer (mCRPC)]Isabel Heidegger, Christoph Becker, Igor Tsaur, et al.
Memo|December 19, 2017
Antiangiogenic therapies in urogenital malignancies: Fiction or fact?Friederike Haidl, David Pfister, Axel Heidenreich, et al.
Urologic Oncology|December 14, 2016
High incidence of clinically significant concomitant prostate cancer in patients undergoing radical cystectomy for bladder cancer: A 10-year single-center experienceIsabel Heidegger, Willi Oberaigner, Wolfgang Horninger, et al.
Aktuelle Urologie|September 6, 2018
[Symptomatic urinary obstruction in patients with metastatic malignancies]Isabel Heidegger, Fabian Steinkohl, Wolfgang Horninger, et al.
Journal of Cancer Research and Clinical Oncology|October 16, 2024
Unraveling molecular characteristics and tumor microenvironment dynamics of neuroendocrine prostate cancerDavid Heimdörfer, Nastasiia Artamonova, Zoran Culig, et al.
Urologic Oncology|June 28, 2020
Emerging promising biomarkers for treatment decision in metastatic castration-resistant prostate cancerMona Kafka, Iris E Eder, Helmut Klocker, et al.
Aktuelle Urologie|January 22, 2026
[Therapy-Associated Neuroendocrine Prostate Cancer (tNEPC): A Diagnostic and Therapeutic Challenge in Uro-Oncology with Emerging Clinical Implications]Gunhild von Amsberg, Arndt Hartmann, Markus Eckstein, et al.
Pageof 16